Mod GRF 1-29 vs MOTS-c
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Mod GRF 1-29
Mod GRF 1-29 (Modified GRF 1-29, also called CJC-1295 without DAC or Tetrasubstituted GRF 1-29) is a modified growth hormone-releasing hormone analog with improved stability over natural GHRH.
Full details →MOTS-c
MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is a mitochondrial-derived peptide that plays a key role in metabolic regulation and has emerged as a significant longevity research target.
Full details →Side-by-Side Comparison
| Aspect | Mod GRF 1-29 | MOTS-c |
|---|---|---|
| Mechanism | Binds to GHRH receptors in the pituitary gland to stimulate growth hormone release. Four amino acid substitutions improve resistance to enzymatic degradation while maintaining biological activity. | Activates AMPK pathway, enhances glucose uptake in skeletal muscle, improves insulin sensitivity, and regulates mitochondrial function. Acts as a metabolic hormone affecting whole-body energy homeostasis. |
| Typical Dosage | Typical dosing: 100-300mcg administered 2-3 times daily, usually combined with a GHRP like Ipamorelin for synergistic effects. | Research protocols typically use 5-10mg administered subcutaneously several times per week. Optimal dosing not yet established. |
| Administration | Subcutaneous injection. Best administered on empty stomach. Short half-life (~30 minutes) necessitates multiple daily doses, unlike DAC version. | Subcutaneous injection. Often combined with exercise protocols as it enhances exercise capacity and metabolic adaptation. |
| Side Effects | Flushing, headache, dizziness, and injection site reactions. Generally well-tolerated. May cause water retention. | Limited human data. Animal studies show good tolerability. May affect energy levels and exercise performance. |
| Best For |
What They Have in Common
Both Mod GRF 1-29 and MOTS-c are commonly used for: